AEGiS-05CROI: HIV-1 entry into cells: targets for drug and vaccine development.

5th Conference on Retroviruses and Opportunistic Infections


Chicago, IL - February 1-5, 1998



HIV-1 entry into cells: targets for drug and vaccine development.

Conf Retroviruses Opportunistic Infect 1998 Feb 1-5; 5th:227 (abstract no. L1)

Sodroski J, Kwong PD, Wyatt R, Desjardins E, Sweet R, Robinson J, Hendrickson W; Department of Cancer Immunology/AIDS, Dana-Farber Cancer Institute, Boston, MA.

The HIV-1 envelope glycoproteins mediate virus entry into target cells by interactions with the viral receptors, CD4 and chemokine receptors. The viral envelope glycoproteins have evolved to perform these functions while, at the same time, evading neutralizing antibodies. Recent advances in determining the structure of the HIV-1 gp120 and gp41 envelope glycoproteins will be discussed in terms of defining appropriate targets for therapeutic and prophylactic intervention.

Keywords: AEGIS, HIV-1, Antigens, CD4, Anti-HIV Agents, Receptors, Chemokine, Pharmaceutical Preparations, Cells, Giant Cells, AIDSKWDaegis,hiv-1,antigens,cd4,anti-hivagents,receptors,chemokine,pharmaceuticalpreparations,cells,giantcells,aids

1998-02-01
L1

Copyright © 1998 - Foundation for Retrovirology and Human Health (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed from National Library of Medicine.